A2 Biotherapeutics, Inc. Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for solid tumors, operating in the biotechnology research sector. It engineers T cells that target loss of genetic material in tumors to selectively kill cancer cells while sparing normal cells. Founded in 2018 by Alexander Kamb, Michael Gallo, and Paul Kang, the company is headquartered at 30301 Agoura Road, Suite 210, Calabasas, California 91301, and employs 51-200 people. The company has raised capital from a range of investors, including The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments, and Hartford HealthCare Endowment. A2 Biotherapeutics reports ongoing clinical development and has announced abstracts accepted for presentation at major oncology conferences, including the 2026 ASCO meeting and prior years such as SITC 2025 and IASLC 2025 World Conference.